What bialoom does

bialoom is a deep tech point-of-care diagnostics start-up established in 2018 and headquartered in Nicosia, Cyprus, operating at the intersection of silicon photonics, plasmonics, and in-vitro diagnostics. The company is developing biosensor-based devices intended to enable rapid diagnosis and treatment of severe infections and anaphylaxis at the point of need, with stated end users including hospital emergency departments, allergy clinics, and private medical practices. Primary customer use cases are tryptase quantification for anaphylaxis diagnosis and acute infection biomarker analysis.

The company's core offering is a proprietary silicon plasmo-photonic biosensor technology that uses plasmonic interferometric sensors on a micrometer-scale sensing area, capable of detecting multiple critical biomarkers from picoliter-scale analytes. Manufacturing leverages standard CMOS semiconductor processes to produce low-cost, multi-sensor biochips embedded in disposable cartridges, with two flagship diagnostic projects: MultiCare (a 2-year, small-scale project completed in June 2023 that validated plasmo-photonic biosensing as an in-vitro diagnostic device for acute infection analysis) and LOTTO (a higher-sensitivity tryptase detection prototype for rapid anaphylaxis diagnosis). The company has pursued AI/ML partnerships as a stated future capability to integrate personalized test outcomes with patient medical records, demographics, and medical statistics, though no implemented AI product is disclosed.

Bialoom is in pre-commercial stage with no disclosed revenue, customers, pricing, or active distribution channels. The business model centers on future sales of disposable biochip cartridges used with a proprietary point-of-care instrument, targeting institutional healthcare buyers via an enterprise field-sales motion. To date the company has been financed primarily through non-dilutive sources — the EU Horizon 2020 research and innovation programme (Grant Agreement No 888337, SepsiCare) and the Cyprus Research and Innovation Foundation Proof of Concept programme (Grant No CONCEPT/0618/0038, LOTTO) — with operational support from incubators Gravity Ventures / CyRIC and co-development relationships with AMO GmbH and RWTH Aachen.

Name

bialoom

Legal name

bialoom

Website

https://bialoom.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

Bialoom is a Nicosia, Cyprus-based deep tech startup developing silicon plasmo-photonic biosensor technology for point-of-care diagnostics of severe infections and anaphylaxis, targeting emergency departments, allergy clinics, and private medical practices. The company is pre-commercial with proof-of-concept validated and grant-funded R&D in progress.

Ownership category

akta.pro rank

Product category

Point-of-Care Diagnostics

NAICS

Analytical Laboratory Instrument Manufacturing (334516), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Laboratory Analytical Instruments (3826), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Biosensors & Lab-on-Chip (BioMEMS) (HDAHALAK)

akta.pro secondary industry

Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels) (HLAAALAC)

Keywords

• Point-of-care diagnostics
• Silicon photonics biosensors
• Plasmonic biochips
• In-vitro diagnostic devices
• Anaphylaxis and sepsis testing

Headquarters

HQ city

Nicosia

HQ country

Cyprus

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

1. Disposable Diagnostic Cartridges: Revenue expected from sale of disposable biochip cartridges for point-of-care diagnostics. The company is developing multi-functional biochips capable of quantifying biomarker signatures from patient blood for faster diagnosis and treatment of severe infections.

Go-to-market motion1 record

Marketing channels4 records

Core offering

Bialoom develops proprietary silicon plasmo-photonic biosensor technology delivered as multi-functional biochips embedded in disposable cartridges capable of quantifying complex biomarker signatures from patient blood. The company targets point-of-care diagnosis of acute infections and anaphylaxis at emergency departments, allergy clinics, hospitals, and private medical practices. Validated programs include MultiCare (acute infections, completed June 2023) and LOTTO (tryptase detection for anaphylaxis).

Product overview

bialoom is a deep tech diagnostics company offering a unified portfolio built around proprietary silicon plasmo-photonic biosensor technology. The core technology powers multi-functional biochips embedded in disposable cartridges capable of quantifying complex biomarker signatures from patient blood. The product portfolio includes two validated diagnostic projects: MultiCare validated the technology for acute infection diagnostics at point of care, while LOTTO demonstrated a prototype for high-sensitivity tryptase detection for anaphylaxis diagnosis. Both products leverage the same underlying platform technology combining silicon photonics, plasmonics, and in-vitro diagnostics.

Differentiator

Problem solved

Functional benefit

Brands

• MultiCare: In-vitro diagnostic device for analysis of acute infections at the point of care using plasmo-photonic biosensing technology. Small-scale 2-year project completed in June 2023.
• LOTTO

Products and services

• MultiCare A plasmo-photonic biosensing in-vitro diagnostic device for analysis of acute infections at the point of care. The MultiCare program validated the underlying biosensor technology, optimized product design for market needs, and established the system proof of concept.
• LOTTO (Low-cost Optical biochip for diagnosis of anaphylaxis at The poinT Of care) A high-sensitivity tryptase detection prototype system enabling rapid anaphylaxis diagnosis at the point of care, designed for use in emergency departments, allergy clinics, and private medical practices.
• Silicon Plasmo-Photonic Biosensor Disposable Cartridges Proprietary multi-functional biochips embedded in disposable cartridges that quantify complex biomarker signatures from patient blood, intended to enable faster, evidence-based diagnosis and treatment of severe infections at the point of need.

Quantifiable outcome

• Point-of-care diagnosis without need for centralized lab equipment

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature4 records

Partnerships

Two partnerships are on record, tiered minor.

• AMO GmbHminorStrategic or Co-development PartnerAMO GmbH is a technology partner. Nature of partnership involves collaboration on silicon photonics and biosensor development. AMO is listed as a partner on the company website.
• RWTH AachenminorStrategic or Co-development PartnerRWTH Aachen University is listed as a partner. The partnership involves research collaboration related to biosensor technology development.

Scale indicators5 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• LumiraDx: Point-of-care diagnostics platform company combining microfluidic and immunoassay technologies on a single instrument with disposable test strips. Highly comparable to bialoom's POC, multi-analyte, disposable-cartridge strategy for acute and time-critical indications.
• T2 Biosystems: Developer of proprietary diagnostic biosensor platforms (T2MR) for sepsis and other bloodstream infections. Directly comparable use case (rapid sepsis diagnostics) and a precedent for a small company commercializing a novel biosensor-based IVD.

Broad incumbents

• QuidelOrtho: Major IVD player with a deep POC portfolio including Triage and Sofia rapid diagnostics used in emergency departments and clinics. Direct overlap with bialoom's anaphylaxis and acute-infection ED targets, and a likely employer/competitor for its core engineering talent.
• Abbott Point of Care: Established i-STAT and rapid diagnostics franchise serving emergency departments and physician offices. Represents both a primary competitor in POC and a source of comparable product-development experience via bialoom team member Kyle Hukari's prior role.
• Cepheid (Danaher): Established molecular diagnostics franchise (GeneXpert) used in hospitals and EDs for rapid syndromic testing including sepsis and infectious disease. Sets the performance and workflow bar bialoom's POC biosensor must match or beat.
• Roche Diagnostics: Global IVD leader with extensive POC and central-lab immunoassay menus for sepsis, cardiac, and allergy markers. Defines the cost, regulatory, and channel benchmark bialoom must compete against in EDs and allergy clinics.

Emerging players

• Paragraf: UK-based graphene-based biosensor company; bialoom Senior Scientist Serife Ustuner previously worked at Paragraf on surface functionalization. Comparable as a deep-tech biosensor startup targeting IVD and life-science markets.
• Abionic: Swiss POC diagnostics company using proprietary nanofluidic biosensor technology for rapid allergy (IgE), sepsis, and other panels. Closely aligned with bialoom on miniaturized, chip-based POC IVDs for anaphylaxis and acute infection.
• Standard BioTools: Life-science instrumentation company focused on single-cell analysis, qPCR, and protein detection; bialoom's Kyle Hukari previously directed engineering there. Comparable as a developer of consumable-driven analytical instruments using semiconductor-like manufacturing.

Others

• Mesa Labs: Specializes in critical measurement and sensor-based products including biological indicators and sterilization monitoring. Adjacent as a sensor/measurement instrumentation peer with a similar deep-tech-to-commercial trajectory.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds4 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about bialoom